moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Other Events
Item 8.01.
| Other Events. |
On April 11, 2017, Moleculin Biotech, Inc. (the Company) issued a
press release announcing that it had appointed Theradex Systems,
Inc. as its contract research organization for its planned Phase
I/II clinical trial for Annamycin for the treatment of relapsed
or refractory acute myeloid leukemia. A copy of the press release
is attached to this report as Exhibit 99.1 and is incorporated by
reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
(d)Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press release dated April 11, 2017 |
About moleculin biotech, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations. moleculin biotech, INC. (NASDAQ:MBRX) Recent Trading Information
moleculin biotech, INC. (NASDAQ:MBRX) closed its last trading session down -0.016 at 0.860 with 169,191 shares trading hands.